Profound Medical Corp. Announces Fourth Quarter and Full Year 2017 Financial Results

Profound Medical (TSX-V:PRN) the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“2017 was truly a transformative year for Profound,” said Arun Menawat, Profound’s CEO. “With the growing success of the pilot commercial launch of TULSA-PRO^® in Europe, combined with the acquisition of Philips’ Sonalleve^® business, Profound made the leap from a development-stage medical device company to a platform company focused on growth. Through the last financing, we now also have the financial resources required to continue to further drive clinical adoption of TULSA-PRO^® in Europe, advance development of the technology toward successful commercialization in the United States, and execute our commercial plans for the Sonalleve^® business.”

Click here to read the full press release.